AR115983A1 - Formulaciones de dendrímeros - Google Patents
Formulaciones de dendrímerosInfo
- Publication number
- AR115983A1 AR115983A1 ARP190102354A ARP190102354A AR115983A1 AR 115983 A1 AR115983 A1 AR 115983A1 AR P190102354 A ARP190102354 A AR P190102354A AR P190102354 A ARP190102354 A AR P190102354A AR 115983 A1 AR115983 A1 AR 115983A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- dendrimer
- compound
- residue
- building units
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000412 dendrimer Substances 0.000 abstract 3
- 229920000736 dendritic polymer Polymers 0.000 abstract 3
- 229960000583 acetic acid Drugs 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000012362 glacial acetic acid Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
- C08G83/004—After treatment of dendrimers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica que comprende un dendrímero liofilizado de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: Núcleo es un compuesto de formula (6), * indica unión covalente a un resto de carbonilo de (BU1); b es 2; BU son unidades de construcción; BUˣ son unidades de construcción de generación x, en donde el número total de unidades de construcción en la generación x del dendrímero de fórmula (1) es igual a 2⁽ˣ⁾ y el número total de BU en el dendrímero de fórmula (1) es igual a (2ˣ - 1)ᵇ; en donde BU tiene la estructura de fórmula (7), # indica unión covalente a un resto de amina de núcleo o un resto amino de BU; + indica una unión covalente a un resto de carbonilo de BU o una unión covalente a W o Z; W es independientemente (PM)ᶜ o (H)ₑ; Z es independientemente (L-AA)ᵈ o (H)ₑ; PM es PEG₁₈₀₀₋₂₄₀₀; L-AA es un enlazador unido covalentemente a un agente activo; en donde L-AA es de fórmula (8), donde A es -N(CH₃) o -S-; Å es el punto de unión a un resto de amina de BUˣ; a condición de que (c + d) £ (2ˣ)ᵇ y d sea ³ 1; y a condición de que si (c + d) < (2ˣ)ᵇ, entonces cualesquier grupos W y Z restantes son (H)ₑ, en donde e es [(2ˣ)ᵇ] - (c + d). Reivindicación 54: Una composición farmacéutica que comprende un compuesto liofilizado de la fórmula (1), (2), (3), (4) ó (5) preparado mediante el procedimiento que comprende las etapas de disolver el compuesto de fórmula (1), (2), (3), (4) ó (5) en ácido acético glacial para formar una disolución, secar por congelación la disolución y sublimar el ácido acético a presión reducida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719319P | 2018-08-17 | 2018-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115983A1 true AR115983A1 (es) | 2021-03-17 |
Family
ID=68084891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102354A AR115983A1 (es) | 2018-08-17 | 2019-08-16 | Formulaciones de dendrímeros |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12115174B2 (es) |
| EP (1) | EP3837017A1 (es) |
| JP (1) | JP7506660B2 (es) |
| KR (1) | KR20210046704A (es) |
| CN (1) | CN112543664A (es) |
| AR (1) | AR115983A1 (es) |
| AU (1) | AU2019322205C1 (es) |
| BR (1) | BR112021002586A2 (es) |
| CA (1) | CA3108648A1 (es) |
| CL (1) | CL2021000389A1 (es) |
| CO (1) | CO2021002980A2 (es) |
| CR (1) | CR20210086A (es) |
| DO (1) | DOP2021000028A (es) |
| EA (1) | EA202190458A1 (es) |
| IL (1) | IL280829B2 (es) |
| MX (1) | MX2021001831A (es) |
| PE (1) | PE20210861A1 (es) |
| PH (1) | PH12021550323A1 (es) |
| SG (1) | SG11202101394YA (es) |
| UY (1) | UY38337A (es) |
| WO (1) | WO2020035815A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5989294B2 (ja) * | 2006-01-20 | 2016-09-07 | スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ | 修飾高分子 |
| TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| CN110124051B (zh) * | 2011-06-06 | 2022-10-21 | 星法马私人有限公司 | 大分子 |
| US20160220689A1 (en) * | 2013-09-10 | 2016-08-04 | Starpharma Pty Ltd. | Macromolecules of dendrimer-platinum conjugates |
| JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
-
2019
- 2019-08-15 US US17/268,632 patent/US12115174B2/en active Active
- 2019-08-15 MX MX2021001831A patent/MX2021001831A/es unknown
- 2019-08-15 JP JP2021507807A patent/JP7506660B2/ja active Active
- 2019-08-15 BR BR112021002586-3A patent/BR112021002586A2/pt unknown
- 2019-08-15 AU AU2019322205A patent/AU2019322205C1/en active Active
- 2019-08-15 CA CA3108648A patent/CA3108648A1/en active Pending
- 2019-08-15 IL IL280829A patent/IL280829B2/en unknown
- 2019-08-15 SG SG11202101394YA patent/SG11202101394YA/en unknown
- 2019-08-15 PE PE2021000209A patent/PE20210861A1/es unknown
- 2019-08-15 CR CR20210086A patent/CR20210086A/es unknown
- 2019-08-15 EP EP19779577.6A patent/EP3837017A1/en active Pending
- 2019-08-15 WO PCT/IB2019/056924 patent/WO2020035815A1/en unknown
- 2019-08-15 CN CN201980052937.4A patent/CN112543664A/zh active Pending
- 2019-08-15 KR KR1020217007686A patent/KR20210046704A/ko unknown
- 2019-08-15 EA EA202190458A patent/EA202190458A1/ru unknown
- 2019-08-16 UY UY0001038337A patent/UY38337A/es unknown
- 2019-08-16 AR ARP190102354A patent/AR115983A1/es unknown
-
2021
- 2021-02-15 PH PH12021550323A patent/PH12021550323A1/en unknown
- 2021-02-15 CL CL2021000389A patent/CL2021000389A1/es unknown
- 2021-02-17 DO DO2021000028A patent/DOP2021000028A/es unknown
- 2021-03-04 CO CONC2021/0002980A patent/CO2021002980A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202190458A1 (ru) | 2021-09-28 |
| MX2021001831A (es) | 2021-04-28 |
| US20220273677A1 (en) | 2022-09-01 |
| IL280829A (en) | 2021-04-29 |
| CL2021000389A1 (es) | 2022-02-25 |
| PH12021550323A1 (en) | 2021-10-04 |
| CR20210086A (es) | 2021-03-19 |
| BR112021002586A2 (pt) | 2021-05-04 |
| UY38337A (es) | 2020-02-28 |
| TW202021575A (zh) | 2020-06-16 |
| CO2021002980A2 (es) | 2021-03-19 |
| KR20210046704A (ko) | 2021-04-28 |
| WO2020035815A1 (en) | 2020-02-20 |
| AU2019322205A1 (en) | 2021-04-08 |
| AU2019322205B2 (en) | 2023-03-16 |
| DOP2021000028A (es) | 2021-03-15 |
| IL280829B1 (en) | 2024-02-01 |
| IL280829B2 (en) | 2024-06-01 |
| SG11202101394YA (en) | 2021-03-30 |
| JP2021534172A (ja) | 2021-12-09 |
| CN112543664A (zh) | 2021-03-23 |
| AU2019322205C1 (en) | 2023-09-07 |
| JP7506660B2 (ja) | 2024-06-26 |
| CA3108648A1 (en) | 2020-02-20 |
| PE20210861A1 (es) | 2021-05-18 |
| US12115174B2 (en) | 2024-10-15 |
| EP3837017A1 (en) | 2021-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020001498A2 (es) | Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7) | |
| ES2561108T3 (es) | Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo | |
| ES2657687T3 (es) | Derivados de pirrolopirimidina para uso en el tratamiento de infecciones virales | |
| JP2019077731A5 (es) | ||
| ECSP099177A (es) | Derivados de quinazolinona e isoquinolinona | |
| PE20191660A1 (es) | Dendrimeros terapeuticos | |
| PE20160665A1 (es) | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x | |
| JP2008522981A5 (es) | ||
| JP2010215657A5 (es) | ||
| AR082995A1 (es) | Profarmacos que comprenden un conjugado de conector de exendina | |
| PE20200698A1 (es) | Gel que comprende clorhexidina | |
| DE60332212D1 (de) | Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator | |
| MX337481B (es) | Composiciones fotosensibilizantes. | |
| CY1115199T1 (el) | Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| JP2013542247A5 (es) | ||
| AR053162A1 (es) | Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma. | |
| SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| RU2011136250A (ru) | Низкомолекулярное полисульфатированное производное гиалуроновой кислоты и содержащее его лекарственное средство | |
| RU2013125021A (ru) | Местные композиции для сохранения или восстановления целостности слизистых оболочек | |
| AR096461A1 (es) | Anticuerpos conjugados de fármacos | |
| AR070352A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto. | |
| HRP20171698T1 (hr) | Upotreba melatonina u liječenju i/ili sprječavanju mukozitisa | |
| JP2014050390A5 (es) | ||
| WO2015183995A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof |